Zacks Investment Research·Sep 3, 2026
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
ACADIA's dual-product portfolio is driving accelerating revenue growth, with 16.4% YoY growth in 2026Q2 and gross margins holding at 90.8%, signaling strong commercial execution. Operating leverage is emerging as SG&A fell to 52% of revenue in 2026Q2 from 64% ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.18+164.1% vs $0.07 | $308M+3.8% vs $297M |
Q2 2026 May 6, 2026 | $0.02-50.0% vs $0.04 | $268M-4.3% vs $280M |
Q1 2026 Feb 25, 2026 | $1.60+1067.9% vs $0.14 | $284M-3.0% vs $293M |
Q4 2025 Nov 5, 2025 | $0.42+200.0% vs $0.14 | $279M+0.8% vs $277M |
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Alyeska Investment Group L.P. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 310,287 shares of the biopharmaceutical company's stock, valued at approximately $7,850,000. Alyeska Investment Group L.P. owned about 0.18% of ACADIA
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the
Benchmark ACAD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ACADIA Pharmaceuticals Inc. (ACAD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.43 | $4.35B | 11.10 | 11.87% | 36.49% | 39.89% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $193.45 | $9.95B | -52.57 | 65.55% | -24.68% | -255.6% | — | |
| $5.24 | $2.31B | 9.36 | 31.26% | 15.79% | 14.95% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $227.53 | $33.62B | 25.77 | 1.39% | 8.39% | 4.52% | — |
ACADIA Pharmaceuticals Inc. (ACAD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ACADIA Pharmaceuticals Inc. (ACAD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 29, 2026·SEC
May 6, 2026·SEC
Get notified when ACAD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACADIA Pharmaceuticals Inc. (ACAD) stock FAQ — growth, dividends, profitability & financials explained
ACADIA Pharmaceuticals Inc. (ACAD) reported $1.14B in revenue for fiscal year 2025. This represents a 26306% increase from $4.3M in 2000.
ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 11.9% over the past year. This is steady growth.
Yes, ACADIA Pharmaceuticals Inc. (ACAD) is profitable, generating $380.5M in net income for fiscal year 2025 (36.5% net margin).
ACADIA Pharmaceuticals Inc. (ACAD) has a return on equity (ROE) of 39.9%. This is excellent, indicating efficient use of shareholder capital.
ACADIA Pharmaceuticals Inc. (ACAD) generated $174.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
